Lessons in Laboratory Compliance from a $30 Million Settlement
‘Lean lab’ setup appears to have caught the eyes of investigators
Keeps You Up-to-Date on Lab Business and Competitive Strategy, Market Trends and Opportunities, and M&A and Investment Activity in Today’s Diagnostic Lab Industry
‘Lean lab’ setup appears to have caught the eyes of investigators
Agency’s annual report to Congress concludes that providers are doing just fine and don’t need a big bump in pay at this time.
The deal closed Feb.22, but the FTC has expressed concerns about the acquisition and Amazon’s business practices in general.
With COVID-19 testing demand all but dried up, labs will have to make—or at least contemplate making—significant changes to their business.
Companies in the COVID-19 diagnostic products market will need to decide whether to wind down their EUA-based investments.
Though Q4 earnings in the lab industry took a beating as predicted, the earnings picture wasn’t nearly as bleak as many had feared.
The health plan issued a new policy expanding coverage of molecular genetic tests for personalized cancer diagnosis, prognosis, and treatment.
Genomics software developer Allelica to collaborate with Taiwanese precision medicine firm to develop a multi-ancestry breast cancer test.
Economic volatility and uncertainty is also making a significant impact on merger and acquisition activity in the diagnostics space.
An effective business case communicates need, benefit, and risks.
Abbott and Roche garnered the lion’s share of new 510(k) lab test approvals in 2022.